Therapeutic targeting of the PI3K pathway has also been reported for the canine B-cell lymphoma cell line 3132, in which exposure to the pan-class I PI3K inhibitor ZSTK474 induced antiproliferative effects [12]. Here, PIK3CG is linked to B-cell non-Hodgkin lymphoma.